Direction at a glance
Gene-editing programmes aim either to cut conserved HIV sequences from infected cells or make target cells resistant to infection. The first challenge is safe delivery to enough relevant cells and tissues.
What the evidence establishes
- A first-in-human CRISPR-based HIV study is registered and should be interpreted through its protocol and posted results.
- Preclinical models show that antiviral drugs and gene editing can be combined, but model results do not establish human cure.
- Off-target editing, immune responses to vectors and incomplete tissue delivery require long-term study.
Next decisive research questions
Limits and responsible interpretation
What this direction does not yet prove
No gene-editing strategy has established a broadly applicable HIV cure. Registry status and conference reports are not substitutes for peer-reviewed clinical outcomes.
Development pathway
| Decision | Required evidence |
|---|---|
| Biological activity | Target engagement and an outcome that cannot be explained by assay noise or selection. |
| Clinical value | Meaningful benefit, adequate follow-up, safety, comparison with current standard care and transparent uncertainty. |
| Generalizability | Diverse populations, subtypes, geographies, ages and clinically relevant comorbidities. |
| Scalability | Manufacturing, delivery, monitoring, price, workforce and community acceptability. |
Principal sources and evidence gateways
Links checked 18 August 202601
EBT-101 first-in-human HIV gene-editing study recordClinicalTrials.gov · Registry · Access checked 18 Aug 2026
↗02CCR5 knockout and antibody secretion in engineered blood stem cellsNature Communications · Primary research · Access checked 18 Aug 2026
↗03ClinicalTrials.gov HIV study registryU.S. National Library of Medicine · Registry · Access checked 18 Aug 2026
↗